Pneumococcal conjugate second or third-dose vaccines (PCVc) in Switzerland

Switzerland: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 92.0% in 2025. ▲ Rising

Latest (2025)
92.0%
Change on year
up 1.1%
World rank
56th
of 194 countries
All-time high
92.0%
in 2025
All-time low
13.0%
in 2008
Years of data
18
2008–2025

Pneumococcal conjugate second or third-dose vaccines (PCVc) in Switzerland, 2008–2025

204060801002008201620252008: 132009: 252010: 372011: 502012: 622013: 752014: 802015: 802016: 802017: 842018: 842019: 842020: 862021: 882022: 892023: 892024: 912025: 92

Source: World Health Organization, Global Health Observatory.

Analysis

The most recent figure for pneumococcal conjugate second or third-dose vaccines (pcvc) in Switzerland is 92.0%, measured in 2025. That is the highest value across all 18 years on record.

That represents a change of up 1.1% on the previous year and up 15.0% over ten years.

Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Switzerland peaked at 92.0% in 2025 and was at its lowest, 13.0%, in 2008.

Switzerland ranks 56th of 194 countries on this measure, in the middle of the range.

The long-run direction has been consistently rising across the 18 years of available data.

Pneumococcal conjugate second or third-dose vaccines (PCVc) in Switzerland, year by year

Annual values for Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC) in Switzerland, 2008 to 2025.
Year Value Change
2008 13.0% —
2009 25.0% +92.3%
2010 37.0% +48.0%
2011 50.0% +35.1%
2012 62.0% +24.0%
2013 75.0% +21.0%
2014 80.0% +6.7%
2015 80.0% +0.0%
2016 80.0% +0.0%
2017 84.0% +5.0%
2018 84.0% +0.0%
2019 84.0% +0.0%
2020 86.0% +2.4%
2021 88.0% +2.3%
2022 89.0% +1.1%
2023 89.0% +0.0%
2024 91.0% +2.2%
2025 92.0% +1.1%

Switzerland compared with similar countries

  • Switzerland's 92.0% is above the median for high income countries, which is 91.0%, 1.0× the median. (63 countries reporting)
  • Switzerland's 92.0% is above the median for Europe & Central Asia, which is 87.0%, 1.1× the median. (51 countries reporting)

Biggest year-on-year movements

Years where Pneumococcal conjugate second or third-dose vaccines (PCVc) in Switzerland changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.

YearChange FromTo
2009 +92.3% 13.0% 25.0%
2010 +48.0% 25.0% 37.0%
2011 +35.1% 37.0% 50.0%

Averages by decade

DecadeAverage LowestHighest Years
2000s 19.0% 13.0% 25.0% 2
2010s 71.6% 37.0% 84.0% 10
2020s 89.2% 86.0% 92.0% 6

Countries ranked near Switzerland

  1. 53 Andorra 93.0% compare
  2. 53 Sierra Leone 93.0% compare
  3. 53 Malaysia 93.0% compare
  4. 56 Fiji 92.0% compare
  5. 56 Turkey 92.0% compare
  6. 56 Libya 92.0% compare
  7. 56 Iceland 92.0% compare

See the full ranking of 207 places →

More health data for Switzerland

All data for Switzerland →

Frequently asked questions

What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Switzerland?
Pneumococcal conjugate second or third-dose vaccines (pcvc) in Switzerland was 92.0% in 2025, according to World Health Organization, Global Health Observatory.
What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Switzerland?
The highest recorded value was 92.0% in 2025.
What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Switzerland?
The lowest recorded value was 13.0% in 2008.
How does Switzerland rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
Switzerland ranks 56th out of 194 countries with data for 2025.
Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in Switzerland?
Over the last ten years it is up 15.0%. The long-run trend across the full record is rising.
Where does this Switzerland data come from?
The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).

Share, cite or embed this page

Cite this page

Pneumococcal conjugate second or third-dose vaccines (PCVc) in Switzerland. Statizoid, drawing on World Health Organization, Global Health Observatory. Retrieved 26 September 2026, from https://health.statizoid.com/stat/pneumococcal-conjugate-second-or-third-dose-vaccines-pcvc-immunization-coverage-by-the/switzerland/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY-NC-SA 3.0 IGO (WHO); please keep the attribution.

<a href="https://health.statizoid.com/stat/pneumococcal-conjugate-second-or-third-dose-vaccines-pcvc-immunization-coverage-by-the/switzerland/">Pneumococcal conjugate second or third-dose vaccines (PCVc) in Switzerland</a> — Statizoid

About this data

Indicator
Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC)
Source
World Health Organization, Global Health Observatory
Licence
CC BY-NC-SA 3.0 IGO (WHO)
Coverage
207 places, 3,723 data points, 2008–2025
Last refreshed